INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Lille Nord de France
Lila, FranciaPublicaciones en colaboración con investigadores/as de University of Lille Nord de France (43)
2024
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
2023
-
Advancements in the Practical Applications of Agents, Multi-Agent Systems and Simulating Complex Systems
Systems
-
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica, Vol. 108, Núm. 11, pp. 2894-2912
-
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
Expert Review of Hematology, Vol. 16, Núm. 11, pp. 835-847
-
Preface
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)
2022
-
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial
European Heart Journal, Vol. 43, Núm. 29, pp. 2783-2797
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Cancer Cell, Vol. 40, Núm. 11, pp. 1358-1373.e8
-
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Annals of Oncology, Vol. 33, Núm. 3, pp. 259-275
-
Preface
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
-
Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Prostate, Vol. 82, Núm. 13, pp. 1237-1247
2021
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946
-
Developing the surgical technique reporting checklist and standards: a study protocol
Gland Surgery, Vol. 10, Núm. 8, pp. 2591-2599
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371